GlassScriptPhysician profile
Debabrata Ghosh
NPI 1356446595
$3,946.68
in general payments reported to CMS, 2019-2025
37 companies · $818 in 2025
The $818 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.37 · 2020: $756 · 2021: $602 · 2022: $530 · 2023: $503 · 2024: $677 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,998.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,998.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $909.40 | 2019-2025 | Briviact, Fintepla, Zilbrysq |
| Neurelis, INC. | $708.01 | 2020-2025 | Valtoco |
| Supernus Pharmaceuticals, INC. | $263.19 | 2021-2025 | Qelbree |
| Collegium Pharmaceutical, INC. | $252.53 | 2025 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $233.10 | 2020-2024 | |
| Genentech USA, INC. | $161.66 | 2022-2025 | Ocrevus, Evrysdi, Ocrevus Zunovo |
| Greenwich Biosciences, INC. | $136.85 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $108.63 | 2023-2025 | Nuplazid |
| Eisai INC. | $93.78 | 2020-2025 | |
| Sk Life Science, INC. | $87.39 | 2021-2025 | |
| Biogen, INC. | $80.18 | 2023-2024 | Spinraza, Tysabri, Vumerity |
| Catalyst Pharmaceuticals, INC. | $76.57 | 2023-2025 | Fycompa |
| Allergan, INC. | $69.02 | 2020-2021 | |
| Tris Pharma INC | $66.73 | 2024-2025 | Dyanavel Xr |
| Abbvie INC. | $54.40 | 2024-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $49.82 | 2020-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Emd Serono, INC. | $48.65 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $48.36 | 2022-2025 | Austedo Xr, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $47.20 | 2019-2021 | |
| Harmony Biosciences LLC | $47.07 | 2025 | |
| Adamas Pharmaceuticals, INC. | $39.33 | 2020-2021 | |
| Banner Life Sciences, LLC | $36.89 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $34.61 | 2024 | |
| Mallinckrodt Hospital Products INC. | $33.77 | 2020-2025 | Acthar |
| Springworks Therapeutics, INC. | $32.64 | 2025 | Gomekli |
| Acorda Therapeutics, INC | $23.38 | 2020-2021 | |
| Tg Therapeutics, INC. | $23.27 | 2025 | |
| Abbott Laboratories | $22.14 | 2024 | Infinity |
| Zogenix INC. | $21.17 | 2021 | |
| Biomarin Pharmaceutical INC. | $21.10 | 2024 | Brineura |
| Grifols USA, LLC | $20.00 | 2024 | Gamunex-C |
| Corium, LLC | $18.81 | 2024 | Azstarys |
| Amgen INC. | $18.33 | 2021 | |
| Lundbeck LLC | $16.35 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.67 | 2021 | |
| Sunovion Pharmaceuticals INC. | $13.97 | 2020 | |
| Neos Therapeutics, LP | $12.71 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debabrata Ghosh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.